{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:27:57Z","timestamp":1787009277798,"version":"build-2736575974"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Liposomal amphotericin B (LAmB) is widely used for prophylaxis in paediatric patients at high risk of invasive fungal diseases (IFD) but its use is off-label and there is significant variability in dosage and frequency. This systematic review was conducted to evaluate the published data on prophylactic LAmB use in the paediatric population and to present the reported proportions of breakthrough IFD and the associated toxicity profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>EMBASE, Medline, Web of Science and the Cochrane Database were systematically searched for primary research reporting on the use of LAmB as prophylaxis for IFD in the paediatric population up to 7 December 2023, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty studies, comprising three clinical trials, 12 cohort studies, two point-prevalence surveys and three pharmacokinetic (PK) studies, with 2015 patients were included. A total of 717 cases presented individual patient data. Breakthrough IFD occurred in 7.2% (49\/676). The most recognized side effects were hypokalaemia in 23.2% (125\/538) and derangement of liver function tests in 15.0% (49\/327). Discontinuation due to toxicity occurred in 6.0% (30\/503) of patients. Of the four studies reporting PK data, two examined serum levels of LAmB, one analysed CSF levels and the remaining study peritoneal levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite widespread use of prophylactic LAmB, this systematic review highlights the paucity of paediatric data supporting its use. The heterogeneity observed in populations, dosing regimens and study design prevents conclusions being reached on its efficacy or the superiority of one dosing regimen. Overall, there is a clear need for further high-quality robust clinical data and targeted PK studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf171","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T09:18:24Z","timestamp":1747819104000},"page":"1792-1802","source":"Crossref","is-referenced-by-count":3,"title":["Liposomal amphotericin B prophylaxis in paediatrics: a systematic review"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7153-2547","authenticated-orcid":false,"given":"Emma V","family":"Thorley","sequence":"first","affiliation":[{"name":"Centre for Neonatal and Paediatric Infection, City St. George\u2019s, University of London , London ,","place":["UK"]},{"name":"Paediatric Infectious Diseases Unit, St George\u2019s University Healthcare NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hatch","sequence":"additional","affiliation":[{"name":"Pharmacy Department, St George\u2019s University Healthcare NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Li","sequence":"additional","affiliation":[{"name":"Pharmacy Department, St George\u2019s University Healthcare NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharlene N","family":"Mashida","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases Unit, St George\u2019s University Healthcare NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5336-8429","authenticated-orcid":false,"given":"Elio","family":"Castagnola","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS Istituto Giannina Gaslini , Genoa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0593-4112","authenticated-orcid":false,"given":"Alessio","family":"Mesini","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS Istituto Giannina Gaslini , Genoa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lehrnbecher","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology, Oncology and Hemostaseology, Goethe University Frankfurt am Main , Frankfurt ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1188-393X","authenticated-orcid":false,"given":"Andreas H","family":"Groll","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Program, Centre for Bone Marrow Transplantation and Department of Pediatric Hematology\/Oncology, University Children\u2019s Hospital , M\u00fcnster ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6586-3358","authenticated-orcid":false,"given":"Adilia","family":"Warris","sequence":"additional","affiliation":[{"name":"MRC Centre for Medical Mycology, Department of Biosciences, Faculty of Life and Health Sciences, University of Exeter , Exeter ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2871-1747","authenticated-orcid":false,"given":"Laura","family":"Ferreras-Antolin","sequence":"additional","affiliation":[{"name":"Centre for Neonatal and Paediatric Infection, City St. George\u2019s, University of London , London ,","place":["UK"]},{"name":"Paediatric Infectious Diseases Unit, St George\u2019s University Healthcare NHS Foundation Trust , London ,","place":["UK"]},{"name":"MRC Centre for Medical Mycology, Department of Biosciences, Faculty of Life and Health Sciences, University of Exeter , Exeter ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"2025070104565162300_dkaf171-B1","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/jpids\/pix046","article-title":"Epidemiology of invasive fungal disease in children","volume":"6","author":"Pana","year":"2017","journal-title":"J Pediatr Infect Dis Soc"},{"key":"2025070104565162300_dkaf171-B2","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S1470-2045(20)30723-3","article-title":"8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation","volume":"22","author":"Groll","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025070104565162300_dkaf171-B3","first-page":"410","article-title":"Clinical practice update of antifungal prophylaxis in immunocompromised children","volume":"32","author":"Ramos","year":"2019","journal-title":"Rev Espanola Quimioter Publicacion Of Soc Espanola Quimioter"},{"key":"2025070104565162300_dkaf171-B4","volume-title":"Liposomal Amphotericin B Product-Specific Bioequivalence Guidance","author":"EMA","year":"2023"},{"key":"2025070104565162300_dkaf171-B5","author":"FDA"},{"key":"2025070104565162300_dkaf171-B6","author":"NICE"},{"key":"2025070104565162300_dkaf171-B7","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1097\/INF.0000000000003402","article-title":"Pediatric antifungal prescribing patterns identify significant opportunities to rationalize antifungal use in children","volume":"41","author":"Ferreras-Antol\u00edn","year":"2022","journal-title":"Pediatr Infect Dis J"},{"key":"2025070104565162300_dkaf171-B8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12879-021-05774-9","article-title":"Antifungal stewardship in a tertiary care paediatric hospital: the PROAFUNGI study","volume":"21","author":"Mendoza-Palomar","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2025070104565162300_dkaf171-B9","doi-asserted-by":"publisher","first-page":"S672","DOI":"10.1093\/ofid\/ofab466.1355","article-title":"1162. Antifungal use in immunocompromised children in Europe: a 12-week multicenter modified point prevalence study (CALYPSO)","volume":"8","author":"Chorafa","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025070104565162300_dkaf171-B10","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025070104565162300_dkaf171-B11","author":"Cancer Research UK"},{"key":"2025070104565162300_dkaf171-B12","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025070104565162300_dkaf171-B13","author":"US Dep Health Hum Serv"},{"key":"2025070104565162300_dkaf171-B14","author":"Cochrane Training"},{"key":"2025070104565162300_dkaf171-B15","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis Without Meta-Analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"2025070104565162300_dkaf171-B16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1046\/j.1439-0507.2001.00706.x","article-title":"Liposomal amphotericin B for prophylaxis of invasive fungal infections in high-risk paediatric patients with chemotherapy-related neutropenia: interim analysis of a prospective study","volume":"44","author":"Uhlenbrock","year":"2001","journal-title":"Mycoses"},{"key":"2025070104565162300_dkaf171-B17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/pbc.21239","article-title":"Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation","volume":"50","author":"Roman","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"2025070104565162300_dkaf171-B18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.clinthera.2010.02.016","article-title":"Once-weekly liposomal amphotericin B as Candida prophylaxis in very low birth weight premature infants: a prospective, randomized, open-label, placebo-controlled pilot study","volume":"32","author":"Arrieta","year":"2010","journal-title":"Clin Ther"},{"key":"2025070104565162300_dkaf171-B19","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1097\/INF.0000000000000335","article-title":"Safety and tolerability of high-dose weekly liposomal amphotericin B antifungal prophylaxis","volume":"33","author":"Hand","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2025070104565162300_dkaf171-B20","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/j.bbmt.2009.08.006","article-title":"Incidence of viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients","volume":"15","author":"Satwani","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025070104565162300_dkaf171-B21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.bbmt.2005.10.010","article-title":"High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study","volume":"12","author":"Mehta","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025070104565162300_dkaf171-B22","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/bjh.16931","article-title":"Benefits of risk-adapted and mould-specific antifungal prophylaxis in childhood leukaemia","volume":"191","author":"Meryk","year":"2020","journal-title":"Br J Haematol"},{"key":"2025070104565162300_dkaf171-B23","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1093\/jac\/dku148","article-title":"Amphotericin B transfer to CSF following intravenous administration of liposomal amphotericin B","volume":"69","author":"Strenger","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2025070104565162300_dkaf171-B24","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1093\/jac\/dkaa149","article-title":"Low-dose liposomal amphotericin B for antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell transplantation","volume":"75","author":"Mendoza-Palomar","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025070104565162300_dkaf171-B25","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1097\/INF.0000000000003189","article-title":"Aspergillus flavus infections in children with leukemia despite liposomal amphotericin-B prophylaxis","volume":"40","author":"Vissing","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"2025070104565162300_dkaf171-B26","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/j.1399-3046.2007.00754.x","article-title":"Aspergillosis in children after liver transplantation: single center experience","volume":"11","author":"Teisseyre","year":"2007","journal-title":"Pediatr Transplant"},{"key":"2025070104565162300_dkaf171-B27","first-page":"124","article-title":"Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation","volume":"1","author":"Ringd\u00e9n","year":"1997","journal-title":"Pediatr Transplant"},{"key":"2025070104565162300_dkaf171-B28","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/antibiotics11050640","article-title":"Therapeutic drug monitoring of amphotericin-B in plasma and peritoneal fluid of pediatric patients after liver transplantation: a case series","volume":"11","author":"Tortora","year":"2022","journal-title":"Antibiotics"},{"key":"2025070104565162300_dkaf171-B29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/1471-2334-12-151","article-title":"Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis","volume":"12","author":"D\u00f6ring","year":"2012","journal-title":"BMC Infect Dis"},{"key":"2025070104565162300_dkaf171-B30","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1111\/j.1469-0691.2011.03483.x","article-title":"Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients","volume":"17","author":"Bochennek","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2025070104565162300_dkaf171-B31","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/jac\/dkp196","article-title":"Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation","volume":"64","author":"Kolve","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2025070104565162300_dkaf171-B32","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1093\/jac\/dkm521","article-title":"Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients","volume":"61","author":"Allinson","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2025070104565162300_dkaf171-B33","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1046\/j.1439-0507.2002.00744.x","article-title":"Pancreatic toxicity after liposomal amphotericin B: pankreastoxizit\u00e4t nach liposomalem Amphotericin B","volume":"45","author":"Stuecklin-Utsch","year":"2002","journal-title":"Mycoses"},{"key":"2025070104565162300_dkaf171-B34","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","article-title":"Liposomal amphotericin B (AmBisome\u00ae): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions","volume":"76","author":"Stone","year":"2016","journal-title":"Drugs"},{"key":"2025070104565162300_dkaf171-B35","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12879-017-2263-6","article-title":"Empiric treatment against invasive fungal diseases in febrile neutropenic patients: a systematic review and network meta-analysis","volume":"17","author":"Chen","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2025070104565162300_dkaf171-B36","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2025070104565162300_dkaf171-B37","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1055\/s-2008-1043890","article-title":"Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer","volume":"210","author":"Groll","year":"1998","journal-title":"Klin Padiatr"},{"key":"2025070104565162300_dkaf171-B38","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/INF.0b013e3181da2171","article-title":"A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia","volume":"29","author":"Maertens","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"2025070104565162300_dkaf171-B39","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/bcp.13521","article-title":"Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations","volume":"84","author":"Andrew","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2025070104565162300_dkaf171-B40","doi-asserted-by":"publisher","first-page":"e01477-16","DOI":"10.1128\/AAC.01477-16","article-title":"Safety, tolerability, and pharmacokinetics of liposomal amphotericin B in immunocompromised pediatric patients","volume":"61","author":"Seibel","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070104565162300_dkaf171-B41","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1086\/319211","article-title":"Mortality and costs of acute renal failure associated with amphotericin B therapy","volume":"32","author":"Bates","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2025070104565162300_dkaf171-B42","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1439-0507.2011.02158.x","article-title":"Adverse interactions between antifungal azoles and vincristine: review and analysis of cases","volume":"55","author":"Moriyama","year":"2012","journal-title":"Mycoses"},{"key":"2025070104565162300_dkaf171-B43","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.3390\/jcm12144637","article-title":"Antifungal drug-drug interactions with commonly used pharmaceutics in European pediatric patients with acute lymphoblastic leukemia","volume":"12","author":"Sienkiewicz-Oleszkiewicz","year":"2023","journal-title":"J Clin Med"},{"key":"2025070104565162300_dkaf171-B44","first-page":"577","article-title":"Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients","volume":"12","author":"Tollemar","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"2025070104565162300_dkaf171-B45","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/sj.bmt.1701543","article-title":"Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study","volume":"23","author":"Kelsey","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"2025070104565162300_dkaf171-B46","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1093\/annonc\/mdl128","article-title":"Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial","volume":"17","author":"Penack","year":"2006","journal-title":"Ann Oncol"},{"key":"2025070104565162300_dkaf171-B47","doi-asserted-by":"publisher","first-page":"e00010","DOI":"10.1128\/CMR.00010-19","article-title":"Extended dosing regimens for fungal prophylaxis","volume":"32","author":"Lehrnbecher","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"2025070104565162300_dkaf171-B48","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s40265-023-01891-8","article-title":"Rezafungin: first approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/7\/1792\/63462941\/dkaf171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/7\/1792\/63462941\/dkaf171.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T04:57:01Z","timestamp":1751345821000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/7\/1792\/8159730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":48,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,6,10]]},"published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf171","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,6,10]]}}}